Back to Online Symposia Home Page
|
|
Program Description
Current data indicate that schizophrenia continues to be a highly prevalent disorder with high relapse rates. Patients with schizophrenia continue to suffer both on a personal and a societal level. Their quality of life remains poor and the high relapse rates dramatically impact both direct and indirect healthcare costs. Even though new therapies continue to emerge, with theoretically-improved safety profiles, nonadherence with medication continues to be an issue.
Learning Objectives
By participating in this activity, you will be able to:
- State three factors that contribute to nonadherence and the impact of nonadherence on healthcare outcomes
- Describe the impact of nonadherence on functional outcomes and quality of life in patients with schizophrenia
- Identify five factors that contribute to the rationale for treatment selection and methods to prevent inappropriate switching to improve adherence and long-term outcomes in patients with schizophrenia
Who Will Benefit
This activity was designed to meet the continuing education needs of psychiatrists and other physicians, physician assistants, registered nurses, psychiatric nurses and advanced practice nurses. Other mental health professionals may find this activity informative and should check with their state licensing and certification boards to determine if it meets their continuing education requirements.
Your Distinguished Faculty
Understanding the Impact of Nonadherence on Outcomes
Alexander L. Miller, MD
Director, Division of Schizophrenia and Related Disorders, Professor of Psychiatry and Pharmacology, University of Texas Health Science Center, San Antonio
Faculty Disclosures
Alexander L. Miller, MD, has been a member of the Speakers Bureau, has served as a consultant for, and has received grants and research support from AstraZeneca, Bristol-Myers Squibb Company, and Pfizer Inc. He has also received grants and research support from Alexza, Eli Lilly and Company, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Research Foundation, and Organon. In addition, he has served as a consultant for Centene, Janssen Research Foundation, and Solvay.
Rationale for Treatment Selection and Prevention of Inappropriate Switching
Allen Frances, MD
Professor Emeritus, Department of Psychiatry, Duke
Chair, DSM-IV Task Force and Expert Consensus Guidelines Project
Faculty Disclosures
Allen Frances, MD, has indicated that he has no relationships to disclose relating to the subject matter of his presentation.
Leslie Citrome, MD, MPH
Director, Clinical Research and Evaluation Facility
Nathan S Kline Institute for Psychiatric Research
Professor of Psychiatry
Department of Psychiatry
New York University School of Medicine
Faculty Disclosures
Leslie Citrome, is a consultant for, has received honoraria from, or has conducted clinical research supported by the following: Abbott Laboratories, AstraZeneca Pharmaceuticals, Avanir Pharmaceuticals, Azur Pharma Inc, Barr Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Forest Research Institute, GlaxoSmithKline, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Pfizer Inc, and Vanda Pharmaceuticals.
|
Commercial Support
Supported through an educational grant by Janssen, L.P., administered by Ortho-McNeil Janssen Scientific Affairs, LLC
Disclaimers
The content of this video activity may include product information that is inconsistent with or outside of the approved labeling for these products in the United States. Before prescribing any medication, you must familiarize yourself with the manufacturer's product information.
To earn continuing education credit, view this online course and complete the posttest and evaluation provided. A passing score of 70% or more must be achieved on the posttest. A link is provided within this online activity to access the posttest and evaluation. You will have the option of printing a Statement of Credit for your records after submission of the evaluation.
CME LLC, Janssen, L.P., and Ortho-McNeil Janssen Scientific Affairs, LLC are not responsible for the speaker's statements, materials, acts or omissions. |
|
Continuing Medical Education
CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME credits from activities presented by ACCME accredited providers may be used toward American Osteopathic Association (AOA) Category 2-A requirements.
The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
CME LLC is approved by the California Board of Registered Nursing, Provider No. CEP12748, and designates this educational activity for 1.0 contact hour for nurses.
The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ toward recertification requirements.
Content Originally Presented: October 12, 2007
Online Date: February 15, 2008
Credit Expiration Date: February 14, 2009
This activity is based on the symposium Improving Patient Adherence in Schizophrenia: Rationale for Treatment Selection To Prevent Inappropriate Switching at the 20th Annual U.S Psychiatric and Mental Health Congress in October, 2007 in Orlando, Fla. Participants who attended the live symposium mentioned above cannot claim credit for this activity.
|
